Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 3,484 adults ages >=18 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferiority to Aflu...